Collaborative to Prevent Central Line Associated Bacteraemia National Collaborative to Prevent CLAB DHB: Team members:
Organisational “Buy –In” Briefly describe how you got organisational buy in, how did you get Clinicians, executives, Managers on board?
What Changes have you tested? Change Tested 1 2 3 Outcome
Most Successful PDSA Cycle?
Measures Summary Provide measures and graphics for the following from Jan to May 2012 (may require more than one slide) - Rate of CLAB per 1, 000 line days Percentage compliance to Insertion Bundle Percentage compliance to Maintenance Bundle No of days between CLAB (Each DHBs can go as far back as they believe they are able to do a retrospective accurate process analysis aligning with the CDC definitions)
Highlights and Lowlights Do you have an insertion bundle check list? Are you able to measure your rate of compliance? Is there variation in your process? Are you able to measure the variation?
Spread Planning – Do you expect to spread the work of your Collaborative teams to the rest of your organisation? – What is the timetable for this? – What (or who) are the appropriate "units" for adopting changes from your change package? (Who will make the decision to begin using the new ideas in their practice? Some examples of potential “units” include doctors, surgeons, emergency departments, hospitals, nursing units in a hospital, clinics, laboratories, or pharmacists. ) – How many total units do you intend to spread to? This could be all eligible units or some defined subset of them. – How will you select these initial units?
Скачать презентацию Collaborative to Prevent Central Line Associated Bacteraemia National
999b18fa6bd29788cda347f3587da5eb.ppt